We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Protein Identified Modifies Gene Expression in Response to Mitochondrial Damage

By LabMedica International staff writers
Posted on 03 Jan 2017
A protein has been identified that causes changes in cellular gene expression in response to stress or disease related impairment in mitochondrial function.

Reduced mitochondrial DNA copy number, mitochondrial DNA mutations or disruption of electron transfer chain complexes induce mitochondria-to-nucleus retrograde signaling, which induces global change in nuclear gene expression ultimately contributing to various human pathologies including cancer. More...
Recent studies suggested that these mitochondrial changes caused transcriptional reprogramming of nuclear genes although the mechanism of this cross talk was not clarified.

Investigators at the University of Pennsylvania (Philadelphia, USA) recently described a mechanism by which mitochondria could drive changes in nuclear gene expression that were associated with tumor progression. They reported in the December 6, 2016, online edition of the journal Cell Discovery that mitochondria-to-nucleus retrograde signaling regulated chromatin acetylation and altered nuclear gene expression through the activity of the protein hnRNAP2 (heterogeneous ribonucleoprotein A2).

To evaluate the role of hnRNPA2 in mitochondria-to-nucleus communication, the investigators traced its activity in cells with depleted levels of mitochondria. Results showed that hnRNPA2 activated gene promoters of stress-associated genes in the nucleus by binding to them. Furthermore, hnRNPA2 activated these genes by acetylating a histone, which loosened the tightly packed chromatin, allowing DNA transcription to proceed more readily. These processes were reversed when mitochondrial DNA content was restored to near normal cell levels.

These findings suggest an important role for mitochondria as determinants of cell fate by altering the expression of large sets of nuclear genes through epigenetic mechanisms.

"Our study provides a rigorous demonstration of a link between mitochondrial function and nuclear gene expression," said senior author Dr. Narayan Avadhani, professor of biochemistry at the University of Pennsylvania. "Since we know that this type of signaling has a direct role in the early stages of cancer progression, the protein involved could be a very valuable target for alleviating this signaling and possibly cancer progression."

Related Links:
University of Pennsylvania


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.